NBIX
Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer
Article Summary
BUY- Neurocrine Biosciences Inc. (Nasdaq: NBIX) announced the appointment of Samir Siddhanti as Chief Business Officer and a member of Neurocrine Biosciences,'s executive Management Committee.
- Siddhani will lead Neurocrine's enterprise growth strategy overseeing business development, corporate strategy, alliance management and program management to maximize value of company's expanding pipeline through both internal innovation and strategic external opportunities, having assumed leadership roles of increasing responsibility across business development and corporate strategy most recently serving as Vice President, Business Development.
- Neurocrine Biosciences,'s recent $2.9 billion acquisition of Soleno Therapeutics also strengthened his role as Program Team Leader for direclidine providing strategic leadership for program's development in schizophrenia and bipolar disorder while helping shape broader muscarinic portfolio strategy.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 28.6% | 25% | 75.0 ptsVery Good (28.6%) - Solid growth |
| EPS Growth Next 5Y ? | 38.7% | 25% | 90.0 ptsExcellent (38.7%) - Strong outlook |
| Target Price Upside ? | 12.6% | 20% | 50.0 ptsMeets Minimum (12.6%) - Target: $201.61 vs Current: $179.05 |
| Gross Margin % ? | 98.2% | 15% | 100.0 ptsExceptional (98.2%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -1.2% | 15% | 20.0 ptsBarely a Dip (-1.2%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About NBIX
- Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
- The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody.
- Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions.
- The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc.
- The company was incorporated in 1992 and is headquartered in San Diego, California.